Hypertension in transplant recipients

Journal of Human Hypertension

Volumn 10, Issue 6, 1996, Pages 395-402

  Singer, D R J ^a,b   Jenkins, G H ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Immunosuppression; Transplantation

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CYCLOSPORIN; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IMMUNOSUPPRESSIVE AGENT; SODIUM; STEROID; TACROLIMUS; THIAZIDE DIURETIC AGENT; VERAPAMIL;

CONFERENCE PAPER; HEART LEFT VENTRICLE HYPERTROPHY; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; KIDNEY DISEASE; RECIPIENT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANCE BLOOD VESSEL; SODIUM BALANCE; VASOCONSTRICTION;

ANIMALS; CYCLOSPORINE; HEART TRANSPLANTATION; HUMANS; HYPERTENSION; SODIUM; VASCULAR RESISTANCE; VASOCONSTRICTION;

EID: 0029841624     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (67)

1. Hosenpud JD et al. The Registry of the International Society for Heart and Lung Transplantation - Twelfth Official Report - 1995. J Heart Lung Transplant 1995; 14: 805-815.
2. The SOLVD Investigators. Effect of Enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-691.
3. Kannel WB, Belanger AJ. Epidemiology of Heart Failure. Am J Med 1991; 121: 951-957.
4. Ozdogan E et al. Factors influencing the development of hypertension following cardiac transplantation. J Heart Transplant 1990; 5: 548-553.
5. Law CM et al. Initiation of hypertension in utero and its amplification throughout life. Br Med J 1993; 306: 24-27.
6. Denton D et al. The effect of increased salt intake on blood pressure in chimpanzees. Nature Med 1995; 1: 1009-1016.
7. Curtis JJ, Luke RG, Jones P, Diethelm AG. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med 1988; 85: 134-138.
8. Singer DRJ et al. Blood pressure and endocrine responses to changes in dietary sodium intake following cardiac transplantation. Circulation 1994; 89: 1153-1189.
9. Braith RW et al. Extra-cellular fluid volume is expanded in heart transplant recipients. Circulation 1995; I: 703A.
10. Singer DRJ et al. Raised plasma atrial natriuretic peptides in cardiac transplant recipients. Br Med J 1986; 293: 1391-1392.
11. Wilkins MR et al. Effect of lower body positive pressure on blood pressure, plasma atrial natriuretic factor concentration, and sodium and water excretion in healthy volunteers and cardiac transplant recipients. Cardiovasc Res 1988; 22: 231-235.
12. Singer DRJ et al. Response to dynamic exercise in cardiac transplant recipients: implications for control of the sodium regulatory hormone atrial natriuretic peptide. Clin Sci 1990; 78: 159-163.
13. Katz AM. Angiotensin II: hemodynamic regulator or growth factor? (Editorial). J Mol Cell Cardiol 1990; 22: 739-747.
14. Grainger DJ et al. Serum concentration of transforming growth factor-β is severely depressed in advanced atherosclerosis. Nature Med 1995; 1: 74-79.
15. Julien J et al. Cyclosporin induced stimulation of the renin-angiotensin system after liver and heart transplantation. Transplantation 1993; 56: 885-891.
16. Ong AC et al. Effect of cyclosporin A on endothelin synthesis by cultured human renal cortical epithelial cells. Nephrol Dial Transplant 1993; 8: 748-753.
17. Cavero PG et al. Effects of orthotopic cardiac transplantation on peripheral vascular function in congestive heart failure: influence of cyclosporine therapy. Am Heart J 1994; 127: 1581-1587.
18. Carrier M, Tronc F, Stewart D, Pelletier LC. Dose- dependent effect of cyclosporin on renal artery resistance of dogs. Am J Physiol 1991; 261: H1791-H1796.
19. Levin ER. Endothelins. New Engl J Med 1995; 333: 356-363.
20. Haynes WG, Clarke JG, Cockcroft JR, Webb DJ. Pharmacology of endothelin-1 in vivo in humans. J Cardiovasc Pharmacol 1991; 17 (Suppl 7): S284-S286.
21. Grieff FM, Loertsher R, Shoaib AS, Stewart DJ. Cyclosporin-induced elevation in circulating endothelin-1 in patients with solid organ transplants. Transplantation 1993; 56: 880-884.
22. Bossaller C et al. Cyclosporin A inhibits endothelium- dependent vasodilatation and vascular prostacyclin production. Eur J Pharmacol 1989; 165: 165-169.
23. Solangi K. L-arginine protects cyclosporin-induced blood pressure elevation in spontaneously hypertensive rats. Clin Res 1990; 38: 349A.
24. Morgan BJ, Lyson T, Scherrer U, Victor RG. Cyclosporin causes sympathetically mediated elevations in arterial pressure in rats. Hypertension 1991; 18: 458- 466.
25. Scherrer U et al. Cyclosporin causes sympathetic activation and hypertension after heart transplantation. N Engl J Med 1990; 323: 693-699.
26. Kaye D, Thompson J, Jennings G, Esler M. Cyclosporin therapy after cardiac transplantation causes hypertension and renal vasoconstriction without sympathetic activation. Circulation 1993; 88: 1101-1109.
27. Myers BD et al. Cyclosporin associated chronic nephropathy. New Engl J Med 1984; 311: 699.
28. Waser M et al. Irreversibility of cyclosporin-induced renal function impairment in heart transplant recipients. J Heart Lung Transp 1993; 12: 846-850.
29. Chervu I, Karubian F, Campese V. The role of endothelial factors; cyclosporin and erythropoietin in hypertension in chronic renal failure. Current Opinion in Cardiol 1992; 7: 776-781.
30. Deray G et al. Effects of cyclosporin on plasma renin activity, catecholaines and prostaglandins in patients with idiopathic uveitis. Am J Nephrology 1988; 8: 298-304.
31. Sehested J et al. Effects of acute administration of cyclosporin on levels of cardiovascular hormones in heart transplant recipients. Am J Cardiol 1993; 72: 484-486.
32. Conte G et al. Acute cyclosporin renal dysfunction reversed by dopamine infusion in healthy subjects. Kidney International 1989; 36: 1086-1092.
33. Garr MD. Cyclosporin augments renal but not systemic vascular reactivity. Am J Physiol 1990; 258: F211- F217.
34. Armitage JM et al. Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. Annals of Thoracic Surgery 1992; 54: 205-210.
35. McDiarmid SV et al. Comparison of renal function in cyclosporine- and FK-506-treated patients after primary orthotopic liver transplantation. Transplantation 1993; 56: 847-853.
36. van de Borne P, Leeman M, Primo G, Degaute J-P. Reappearance of a normal circadian rhythm of blood pressure after cardiac transplantation. Am J Cardiol 1992; 69: 794-801.
37. Benediktsson R, Edwards CR. Apparent mineralocorticoid excess. J Hum Hypertens 1994; 8: 371-375.
38. Bevan AT, Honour AJ, Scott FG. Direct arterial pressure recording in unrestricted man. Clin Sci 1969; 36: 329-344.
39. Spallone V et al. Relationship between the circadian rhythms of blood pressure and sympathovagal balance in diabetic autonomic neuropathy. Diabetes 1993; 42: 1745-1752.
40. Wilson RF et al. Evidence for structural sympathetic reinnervation after orthotopic cardiac transplantation in humans. Circulation 1991; 83: 1210.
41. Bernardi L et al. Non-respiratory components of heart rate variability in heart transplant recipients: evidence of autonomic reinnervation. Clin Sci 1994; 86: 537- 545.
42. De Marco T et al. Iodine-123 Metaiodobenzylguanidine Scintigraphic assessment of the transplanted human heart: evidence of late reinnervation. J Am Coll Card 1995; 25: 927-931.
43. Ramaekers D et al. Heart rate variability in heart transplant recipients: evidence of reinnervation. Pace 1995; 18 (Part 2): 1738.
44. Idema RN et al. Decreased circadian blood pressure variation up to three years after heart transplantation. Am J Cardiol 1994; 73: 1006.
45. Jenkins GH, Grieve L, Yacoub MH, Singer DRJ. Left ventricular mass and diurnal variation in blood pressure with time after cardiac transplant. J Hum Hypertens 1996; 6: 413-414.
46. Reeves RA, Shapiro AP, Thompson ME, Johnsen A-M. Loss of nocturnal decline in blood pressure following cardiac transplantation. Circulation 1986; 73: 401- 408.
47. Pickering TG, Devereux R. Ambulatory monitoring of blood pressure as a predictor of cardiovascular risk. Am Heart J 1987; 114: 925-928.
48. Julien J et al. Mid-term echographic evaluation of systolic function after cardiac transplantation (Fre). Archives Des Maladies Du Cœur Et Des Vaisseaux 1990; 83: 495-500.
49. Larson DF, Copeland JG, Russell DH. Catecholamine- induced cardiac hypertrophy in a denervated, hemodynamically non-stressed heart transplant. Life Sciences 1985; 36: 2477-2489.
50. Milano CA et al. Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. PNAS USA 1994; 91: 10109-10113.
51. Dietary Reference Values for Food Energy and Nutrients for the United Kingdom. Panel on Dietary Reference Values of the Committee on Medical Aspects of Food Policy. HMSO: London, 1991: 210. Report on Health and Social Subjects; vol 41.
52. Collins R et al. Blood pressure, stroke and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of the randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
53. Angermann CE et al. Regression of left ventricular hypertrophy in hypertensive heart transplant recipients treated with enalapril, furosemide, and verapamil. Circulation 1991; 84: 583-593.
54. Weinberger MH. Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients. J Cardiovasc Pharmacol 1985; 7 (Suppl 1): S52-S55.
55. Yusuf S et al. Effect of B-blockade on dynamic exercise in human heart transplant recipients. J Heart Transpl 1985; 4: 312-314.
56. Day JL, Metcalfe J, Simpson CN. Adrenergic mechanisms in control of plasma lipid concentrations. Br Med J 1982; 284: 1145-1148.
57. Valantine H et al. Cost Containment: coadministration of Diltiazem and Cyclosporin after heart transplantation. J Heart Lung Transplant 1992; 11: 1-8.
58. Lindholm A, Henricsson S. Verapamil inhibits cyclosporin metabolism. Lancet 1987; i: 1263.
59. Morales JM et al. Long-term protective effect of a calcium antagonist on renal function in hypertensive renal transplant patients on cyclosporine therapy: a 5- year prospective randomised study. Trans Proc 1994; 26: 2598-2599.
60. McFadden JP et al. Cyclosporin decreases nifedipine metabolism. Br Med J 1989; 299: 1224.
61. Bourbigot B et al. Nicardipine increases cyclosporin blood levels. Lancet 1986; i: 1447.
62. Elliott WJ, Murphy MB, Karp R. Long-term preservation of renal function in hypertensive heart transplant recipients treated with enalapril and a diuretic. J Heart Lung Trans 1991; 10: 373-379.
63. Brozena SC, Johnson MR, Ventura HO, Naftel DC. Effectiveness of diltiazem or lisinopril for treatment of hypertension in cardiac transplant recipients: a prospective; randomised multicentre trial. Cardiac Transplant Research Database Group. Circulation 1993; 88: 1480.
64. Hartmann A et al. Effects of nitrendipine and lisinopril on blood pressure and sodium excretion in cyclosporin associated hypertension in heart transplant recipients. Cardiology 1983; 83: 141-149.
65. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987; 316: 1429-35.
66. Pfeffer MA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-677.
67. Swedberg K et al. Effects of early administration of enalapril on mortality in patients with acute myocardial infarction (CONSENSUS II). N Engl J Med 1992; 327: 678-84.